111 related articles for article (PubMed ID: 30320338)
1. NF‑κB inhibitor DHMEQ inhibits titanium dioxide nanoparticle‑induced interleukin‑1β production: Inhibition of the PM2.5‑induced inflammation model.
Fukatsu H; Koide N; Tada-Oikawa S; Izuoka K; Ikegami A; Ichihara S; Ukaji T; Morita N; Naiki Y; Komatsu T; Umezawa K
Mol Med Rep; 2018 Dec; 18(6):5279-5285. PubMed ID: 30320338
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages.
Suzuki E; Sugiyama C; Umezawa K
Biomed Pharmacother; 2009 Jun; 63(5):351-8. PubMed ID: 18635336
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Suzuki E; Umezawa K
Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
[TBL] [Abstract][Full Text] [Related]
4. A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice.
Funakoshi T; Yamashita K; Ichikawa N; Fukai M; Suzuki T; Goto R; Oura T; Kobayashi N; Katsurada T; Ichihara S; Ozaki M; Umezawa K; Todo S
J Crohns Colitis; 2012 Mar; 6(2):215-25. PubMed ID: 22325176
[TBL] [Abstract][Full Text] [Related]
5. Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodelling in murine models of asthma.
Shimizu K; Konno S; Ozaki M; Umezawa K; Yamashita K; Todo S; Nishimura M
Clin Exp Allergy; 2012 Aug; 42(8):1273-81. PubMed ID: 22805475
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
7. Titanium dioxide induces different levels of IL-1beta production dependent on its particle characteristics through caspase-1 activation mediated by reactive oxygen species and cathepsin B.
Morishige T; Yoshioka Y; Tanabe A; Yao X; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Biochem Biophys Res Commun; 2010 Feb; 392(2):160-5. PubMed ID: 20059972
[TBL] [Abstract][Full Text] [Related]
8. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review.
Lin Y; Ukaji T; Koide N; Umezawa K
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510517
[TBL] [Abstract][Full Text] [Related]
10. Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
Suzuki E; Ninomiya Y; Umezawa K
Biochem Biophys Res Commun; 2009 Feb; 379(2):379-83. PubMed ID: 19103154
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
Takatsuna H; Morita S; Nagatsu T; Sawada M; Umezawa K
Biomed Pharmacother; 2005 Jul; 59(6):318-22. PubMed ID: 15932789
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
[TBL] [Abstract][Full Text] [Related]
13. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage.
Kuraya D; Watanabe M; Koshizuka Y; Ogura M; Yoshida T; Asahi Y; Kamachi H; Nakamura T; Harashima H; Ozaki M; Umezawa K; Matsushita M; Yamashita K; Todo S
Transplantation; 2013 Sep; 96(5):445-53. PubMed ID: 23900151
[TBL] [Abstract][Full Text] [Related]
15. Anti‑inflammatory effects of the NF‑κB inhibitor dehydroxymethylepoxyquinomicin on ARPE‑19 cells.
Ando Y; Sato Y; Kudo A; Watanabe T; Hirakata A; Okada AA; Umezawa K; Keino H
Mol Med Rep; 2020 Jul; 22(1):582-590. PubMed ID: 32377746
[TBL] [Abstract][Full Text] [Related]
16. The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
Lampiasi N; Azzolina A; Umezawa K; Montalto G; McCubrey JA; Cervello M
Cancer Lett; 2012 Sep; 322(1):35-44. PubMed ID: 22343223
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of MMP-2-mediated cellular invasion by NF-κB inhibitor DHMEQ in 3D culture of breast carcinoma MDA-MB-231 cells: A model for early phase of metastasis.
Ukaji T; Lin Y; Okada S; Umezawa K
Biochem Biophys Res Commun; 2017 Mar; 485(1):76-81. PubMed ID: 28188787
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the NF-κB pathway as a candidate therapeutic strategy for cryopyrin-associated periodic syndrome.
Shimogaki S; Ito S; Komatsu S; Koike R; Miyasaka N; Umezawa K; Kubota T
Mod Rheumatol; 2014 May; 24(3):517-24. PubMed ID: 24252030
[TBL] [Abstract][Full Text] [Related]
20. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, prevents inflammatory injury induced by interferon-gamma and histamine in NCTC 2544 keratinocytes.
Cardile V; Libra M; Caggia S; Frasca G; Umezawa K; Stivala F; Mazzarino MC; Bevelacqua Y; Coco M; Malaponte G
Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):679-83. PubMed ID: 20337659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
